REGENXBIO

We are a clinical-stage biotechnology company founded in 2008, focused on gene therapy. We aim to improve lives with the potential of gene therapy, developing AAV Therapeutics. We use our NAV® Technology Platform with AAV viral vectors to deliver genes to cells, which can address genetic defects or help cells produce therapeutic proteins. These product candidates are designed for long-lasting effects from a single dose.

We are developing AAV Therapeutics mainly for retinal and rare diseases. Our candidates include ABBV-RGX-314 for wet age-related macular degeneration (AMD) and diabetic retinopathy (in collaboration with AbbVie). Other programs are RGX-202 for Duchenne muscular dystrophy and RGX-121 for MPS II. Our AAV Therapeutic platform has been used in therapies like Novartis’ ZOLGENSMA for spinal muscular atrophy. Thousands of patients have been treated with investigational and approved products built on this platform.

Beyond our own product development, we license our NAV® vectors to other companies for new medicines. We have over 100 novel AAV vectors, late-stage clinical programs, and in-house commercial-ready manufacturing.

We aim to improve lives with the potential of gene therapy. Our mission is to innovate in gene therapy, aiming to deliver one-time treatments for common and rare diseases. We believe what we do matters to patients, their families, and their communities.

Our culture focuses on patients, drives for results, and encourages collaboration. Trust among employees and a commitment to developing gene therapy products for patients with limited options support these aspects. We emphasize being nimble and efficient, recognizing and rewarding perseverance, and holding ourselves accountable to serve patients. Our core values guide how we work.

REGENXBIO has 201-500 employees. Its culture focuses on patients, drives for results, and encourages collaboration. Employees are expected to trust each other and commit to developing gene therapy products for patients with limited options. The company aims to be nimble and efficient, recognizing and rewarding perseverance. Accountability in serving patients is also important. The Washington Post recognized REGENXBIO as a Top Workplace four times from 2021-2025.

We offer a competitive benefits package. This includes market-competitive salaries, an annual bonus, and education assistance. For retirement, we provide a plan with an employer match. All employees are eligible for stock options. Additional benefits include summer hours and professional development resources.